Virtu Financial LLC Makes New Investment in Harrow, Inc. (NASDAQ:HROW)

Virtu Financial LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 6,019 shares of the company’s stock, valued at approximately $271,000.

Several other large investors have also modified their holdings of HROW. Bank of New York Mellon Corp raised its stake in Harrow by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock valued at $1,843,000 after buying an additional 12,580 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Harrow by 2,730.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after acquiring an additional 2,048 shares in the last quarter. nVerses Capital LLC bought a new position in Harrow during the second quarter worth $33,000. Drive Wealth Management LLC boosted its holdings in Harrow by 63.1% in the second quarter. Drive Wealth Management LLC now owns 29,551 shares of the company’s stock worth $617,000 after purchasing an additional 11,434 shares during the period. Finally, Rhumbline Advisers increased its stake in Harrow by 8.2% during the second quarter. Rhumbline Advisers now owns 43,021 shares of the company’s stock valued at $899,000 after purchasing an additional 3,253 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Harrow Stock Performance

HROW stock opened at $35.08 on Wednesday. Harrow, Inc. has a 1 year low of $9.13 and a 1 year high of $59.23. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -37.81 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock’s fifty day moving average is $45.84 and its two-hundred day moving average is $36.31.

Wall Street Analysts Forecast Growth

HROW has been the subject of several research reports. Lake Street Capital lifted their price target on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a report on Friday, October 4th. Craig Hallum raised their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th. Finally, B. Riley lowered their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.